The size of the Middle East and Africa Injectable Drug Delivery Market was valued at USD 4023.77 Million in 2022. It is further estimated to be growing at a CAGR of 11.93% and worth USD 7069.13 Million by 2027.
The Middle East and Africa market is majorly expected to be growing due to increased public awareness and a large population of chronic disease patients. The rise of chronic diseases, technological advancements in pharmaceutical technology, high funds for research and development, and the growth of the medical industry. The growing incidence of AIDS, diabetes, Alzheimer's disease, cancer, and arthritis has led to new drug delivery methods. This has increased the demand for advanced medical products.
With the success of the health awareness programs against HIV and tuberculosis, the death rate is decreasing in South Africa, and life expectancy is increasing. According to the World Health Organization, there is an increase in cancer patients in the country. The MEA region has seen a steady rise in the population, especially people over age 60 and above. The increase in the geriatric population and the increasing prevalence of cardiovascular diseases are driving the market growth in these countries.
Advanced technologies, preference of individual therapy, and controlled drug release by injectable drug delivery are growing the product's popularity. Due to the rapidly changing market for the use of injectable drug delivery technology, medical device companies that can launch new innovative equipment to expand their product portfolios will gather enormous benefits. In 2018, Israeli scientists developed cutting-edge drug delivery technology used with long-wave light to deliver drugs.
However, factors such as fear of injury and risk of infection, high development costs, poor reimbursement plans, and a strict regulatory framework are the main challenges faced by the MEA injectable drug delivery market over the forecast period.
This research report on the Middle East and Africa injectable drug delivery market has been segmented and sub-segmented into the following categories:
By Device Type:
By Therapeutic use:
By End User:
The Middle East region is estimated to dominate the studied market, attributing to the increased elderly population more prone to chronic diseases. In turkey, a senior population of 7.25 million in 2018 is a jump of around 16.55% from approximately 6.28 million in 2014. In addition, according to NCBI, an estimated 3.48 million adults living in Turkey were reported to be affected by some form of cardiovascular disease in 2016.
According to an article published in 2018, Saudi Arabia's senior population aged 60 and over will reach 25.6% of the country's total population by 2050. While, the number of people aged 80 and above is predicted to reach 1.68 million, or 4.56% of the total population. In Saudi Arabia, this increase in the elderly population results in higher healthcare spending, which will lead to significant market growth in the coming years.
Regions in MEA such as Qatar, South Africa, Oman, and United Arab Emirates have seen an increasing prevalence of cardiovascular disease, which has become a cause of significant public health concern leading to nearly 46.8% of the total death rate. As a result, public healthcare officials focus on growing awareness and free camps for early detection for a better prognosis, leading to a better quality of life. These factors are driving the growth of the market during the projected period.
KEY MARKET PLAYERS:
Companies playing an influential role in the Middle East & Africa injectable drug delivery market profiled in this report are Antares Pharmaceuticals Ltd, Baxter International, Becton Dickinson Company, Elcam Medical, Eli Lily and Company, Unilife Corporation, and West Pharmaceutical Inc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com